MindBio Therapeutics Corp.
MBIO
CNSX
| Weiss Ratings | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | -25.00% | |||
| 60-Day Total Return | -25.00% | |||
| 90-Day Total Return | -57.14% | |||
| Year to Date Total Return | -25.00% | |||
| 1-Year Total Return | -78.57% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -71.43% | |||
| 52-Week Low % Change | 33.33% | |||
| Price | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.07 | |||
| 52-Week Low Price | $0.02 | |||
| 52-Week Low Price (Date) | Dec 17, 2024 | |||
| 52-Week High Price (Date) | Mar 14, 2024 | |||
| Valuation | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.99M | |||
| Enterprise Value | 5.03M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -80.54% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -22.22 | |||
| Price/Book (Q) | -0.78 | |||
| Enterprise Value/Revenue (TTM) | -38.49 | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | 122.99 | |||
| Enterprise Value/EBIT | -9.76 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 135.17M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 1055 West Georgia Street Vancouver, BC V6E 4N7 | |||
| Website | www.mindbiotherapeutics.com | |||
| Country | Canada | |||
| Year Founded | 2021 | |||
| Profitability | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 394.18% | |||
| Profit Margin | 307.34% | |||
| Management Effectiveness | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -339.30% | |||
| Return on Equity | -- | |||
| Income Statement | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -130.70K | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | -130.70K | |||
| EBITDA (TTM) | 40.90K | |||
| EBIT (TTM) | -515.20K | |||
| Net Income (TTM) | -401.70K | |||
| Net Income Avl. to Common (TTM) | -401.70K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -857.85% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | -500.00% | |||
| Balance Sheet | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 46.50K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 88.50K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -3.69M | |||
| Current Ratio (Q) | 0.025 | |||
| Book Value Per Share (Q) | -$0.03 | |||
| Total Assets (Q) | 88.50K | |||
| Total Current Liabilities (Q) | 3.58M | |||
| Total Debt (Q) | 3.12M | |||
| Total Liabilities (Q) | 3.78M | |||
| Total Common Equity (Q) | -3.65M | |||
| Cash Flow | MBIO - CNSX | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 93.80K | |||
| Net Change in Cash (TTM) | -19.00K | |||
| Levered Free Cash Flow (TTM) | -285.50K | |||
| Cash from Operations (TTM) | -67.30K | |||
